Younger Matched Unrelated Donors Confer Decreased Relapse Compared to Older Sibling Donors in Older B-cell ALL Patients Undergoing Allogeneic Hematopoietic Cell Transplantation.

[1]  K. Rezvani,et al.  Haploidentical vs matched unrelated donors for patients with ALL: donor age matters more than donor type , 2023, Blood advances.

[2]  M. Perales,et al.  Post-Transplant Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil As the New Standard for Graft-Versus-Host Disease (GVHD) Prophylaxis in Reduced Intensity Conditioning: Results from Phase III BMT CTN 1703 , 2022, Blood.

[3]  M. Pasquini,et al.  Updated Trends in Hematopoietic Cell Transplantation in the United States with an Additional Focus on Adolescent and Young Adult Transplantation Activity and Outcomes. , 2022, Transplantation and cellular therapy.

[4]  M. Copland,et al.  In-vivo T-cell depleted reduced-intensity conditioned allogeneic haematopoietic stem-cell transplantation for patients with acute lymphoblastic leukaemia in first remission: results from the prospective, single-arm evaluation of the UKALL14 trial , 2022, The Lancet. Haematology.

[5]  R. Vij,et al.  Relapse and Disease-Free Survival in Patients With Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Cell Transplantation Using Older Matched Sibling Donors vs Younger Matched Unrelated Donors. , 2022, JAMA oncology.

[6]  A. Artz,et al.  Allogeneic hematopoietic cell transplantation for older patients. , 2021, Hematology. American Society of Hematology. Education Program.

[7]  M. Krem,et al.  Haploidentical vs sibling, unrelated, or cord blood hematopoietic cell transplantation for acute lymphoblastic leukemia , 2021, Blood advances.

[8]  G. Cuvelier,et al.  National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IIa. The 2020 Clinical Implementation and Early Diagnosis Working Group Report , 2021, Transplantation and cellular therapy.

[9]  J. Dipersio,et al.  Biology of Disease Relapse in Myeloid Disease: Implication for Strategies to Prevent and Treat Disease Relapse After Stem-Cell Transplantation. , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  M. Geyer,et al.  Pediatric-inspired chemotherapy incorporating pegaspargase is safe and results in high rates of minimal residual disease negativity in adults up to the age of 60 years with Philadelphia chromosome-negative acute lymphoblastic leukemia , 2020, Haematologica.

[11]  B. Shaw,et al.  Likelihood of Proceeding to Allogeneic Hematopoietic Cell Transplantation in the United States after Search Activation in the National Registry: Impact of Patient Age, Disease and Search Prognosis. , 2020, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[12]  D. Neuberg,et al.  Short Telomere Length Predicts Non-Relapse Mortality after Stem Cell Transplantation for Myelodysplastic Syndrome. , 2020, Blood.

[13]  M. Graham,et al.  Severity of cytokine release syndrome and its association with infections after T-cell replete haploidentical related donor transplantation. , 2020, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[14]  R. Larson,et al.  Hematopoietic Cell Transplantation in the Treatment of Adult Acute Lymphoblastic Leukemia: Updated 2019 Evidence-Based Review from the American Society for Transplantation and Cellular Therapy. , 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[15]  M. B. Abid.  Could the menagerie of the gut microbiome really cure cancer? Hope or hype , 2019, Journal of Immunotherapy for Cancer.

[16]  N. Kröger,et al.  Biology-Driven Approaches to Prevent and Treat Relapse of Myeloid Neoplasia after Allogeneic Hematopoietic Stem Cell Transplantation. , 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[17]  R. Strong,et al.  Patient HLA Germline Variation and Transplant Survivorship. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  D. Porter,et al.  Development of an Unrelated Donor Selection Score Predictive of Survival after HCT: Donor Age Matters Most. , 2018, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[19]  B. Sandmaier,et al.  Comparing outcomes of matched related donor and matched unrelated donor hematopoietic cell transplants in adults with B‐Cell acute lymphoblastic leukemia , 2017, Cancer.

[20]  D. Marks,et al.  A Stem Cell Donor for Every Adult Requiring an Allograft for Acute Lymphoblastic Leukemia? , 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[21]  J. Dipersio,et al.  The effect of donor characteristics on survival after unrelated donor transplantation for hematologic malignancy. , 2016, Blood.

[22]  M. McCarthy,et al.  Age-related clonal hematopoiesis associated with adverse outcomes. , 2014, The New England journal of medicine.

[23]  A. Viale,et al.  The effects of intestinal tract bacterial diversity on mortality following allogeneic hematopoietic stem cell transplantation. , 2014, Blood.

[24]  B. Leber,et al.  Long-term outcome of a pediatric-inspired regimen used for adults aged 18–50 years with newly diagnosed acute lymphoblastic leukemia , 2014, Leukemia.

[25]  M. Perales,et al.  Who is the better donor for older hematopoietic transplant recipients: an older-aged sibling or a young, matched unrelated volunteer? , 2013, Blood.

[26]  K. Kawa,et al.  Allogeneic stem cell transplantation for adult Philadelphia chromosome-negative acute lymphocytic leukemia: comparable survival rates but different risk factors between related and unrelated transplantation in first complete remission. , 2010, Blood.

[27]  M. Maris,et al.  Nonmyeloablative allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  M. Tormo,et al.  Outcome after relapse of acute lymphoblastic leukemia in adult patients included in four consecutive risk-adapted trials by the PETHEMA Study Group , 2010, Haematologica.

[29]  M. Labopin,et al.  Reduced intensity conditioning compared with myeloablative conditioning using unrelated donor transplants in patients with acute myeloid leukemia. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  J. Sierra,et al.  Unrelated donor transplants in adults with Philadelphia-negative acute lymphoblastic leukemia in first complete remission. , 2008, Blood.

[31]  J. Klein,et al.  Classification of HLA-matching for retrospective analysis of unrelated donor transplantation: revised definitions to predict survival. , 2007, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[32]  Chad A Shaw,et al.  Aging Hematopoietic Stem Cells Decline in Function and Exhibit Epigenetic Dysregulation , 2007, PLoS biology.

[33]  Rajesh Chopra,et al.  Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study. , 2007, Blood.

[34]  M. Tallman,et al.  Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993. , 2005, Blood.

[35]  V. Diehl,et al.  Outcome of allogeneic hematopoietic stem-cell transplantation in adult patients with acute lymphoblastic leukemia: no difference in related compared with unrelated transplant in first complete remission. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  B. Löwenberg,et al.  Unrelated marrow transplantation for adult patients with poor-risk acute lymphoblastic leukemia: strong graft-versus-leukemia effect and risk factors determining outcome. , 2001, Blood.

[37]  L. Kumar,et al.  Leukemia: management of relapse after allogeneic bone marrow transplantation. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  A. Rimm,et al.  Graft-versus-leukemia reactions after bone marrow transplantation. , 1990, Blood.

[39]  K. Imai.  Treatment of relapsed or refractory acute lymphoblastic leukemia. , 2017, [Rinsho ketsueki] The Japanese journal of clinical hematology.

[40]  T. Naoe,et al.  Allogeneic hematopoietic stem cell transplantation as part of postremission therapy improves survival for adult patients with high‐risk acute lymphoblastic leukemia , 2006, Cancer.